{'fraction_non_alphanumeric': 0.021212121212121213, 'fraction_numerical': 0.00909090909090909, 'mean_word_length': 6.184782608695652, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Fighting sinus‐derived Staphylococcus aureus biofilms in vitro with a bacteriophage‐derived muralytic enzyme

Staphylococcus aureus biofilms are a nidus for exacerbation of infectious conditions including chronic rhinosinusitis (CRS). Resistance of biofilms to current therapeutics stresses the need for the development of novel anti‐biofilm strategies. The chimeric muralytic enzyme P128 was specifically engineered to target Staphylococcal sp. by combining the cell wall binding domain of lysostaphin and the peptidoglycan‐degrading murein hydrolase derived from phage K. This study assessed the anti‐biofilm activity of P128 against sinus‐derived S. aureus.